Why Doctors Are Testing An Epilepsy Drug For Alcoholism | WAMU 88.5 - American University Radio

NPR : News

Filed Under:

Why Doctors Are Testing An Epilepsy Drug For Alcoholism

In the hunt for new ways to help people fight alcoholism, doctors are studying gabapentin, a generic drug that's commonly used to treat epilepsy and fibromyalgia.

In a 12-week clinical trial conducted by the Scripps Research Institute, people taking taking gabapentin were much better at reducing their alcohol intake than those who got a placebo. The research, involving 150 people, was funded by the National Institutes of Health.

All the volunteers enrolled in the trial received counseling. Some took placebo pills, the rest got either 900 milligrams or 1,800 milligrams of gabapentin each day. People taking a higher dose of the drug refrained from heavy drinking twice as often as the placebo group, and practiced complete abstinence four times as often.

The results were published in JAMA Internal Medicine.

Psychiatrist Barbara J. Mason, who led the study, says gabapentin appears to work because it eases the most common withdrawal symptoms. "Gabapentin improved sleep and mood in people who were cutting down or quitting drinking," she tells Shots. Sleeplessness and anxiety are often what cause people to regress and start drinking again, she says.

Another factor in gabapentin's favor, she says, is that it isn't broken down by the liver, "an organ that's often damaged in people with alcohol dependence." Of three FDA-approved drugs for alcoholism, two pose potential liver risks, she says. Gabapentin passes from the blood through the kidney and into urine pretty much unchanged.

Like any drug, gabapentin has potential side effects. Drowsiness, nausea and blurred vision are some. And the drug hasn't been approved for treatment of alcohol dependence.

Gabapentin, sold under the brand name Neurontin, has a bit of a rocky history. In the early 2000s, Pfizer and its Parke-Davis unit got in trouble for pushing the drug for a variety of unapproved uses.

But Mason says the fact that her work is funded by the NIH, plus the fact that it's a generic formulation, will distance her work from that scandal.

"It's not magic, and making a big behavioral change is hard work," she says. But to ignore a drug that appears effective, she says, '"is not taking advantage of all the tools in the toolbox."

Still, the drug hasn't been approved by the Food and Drug Administration for use in treatment of alcohol dependence and there's no sign it will be anytime soon.

Copyright 2013 NPR. To see more, visit http://www.npr.org/.

NPR

Comedian George Carlin Is National Portrait Gallery's Newest Face

NPR's Audie Cornish talks to Kelly Carlin, the daughter of the late comedian George Carlin, about the Smithsonian National Portrait Gallery's unveiling of her father's portrait Friday.
NPR

Calif. Governor Can't Make It Rain, But Can Make Relief Money Pour

California Gov. Jerry Brown signed his sweeping $1.1 billion emergency drought relief bill Friday. It funds water infrastructure improvements like flood control and aid for farmworkers.
NPR

Nigerian President Faces Tough Reelection Campaign

Nigerians head to the polls Saturday to vote for their new president. The incumbent Goodluck Jonathan faces former military leader, Muhammadu Buhari, who says he's tough on security and corruption.
NPR

App That Aims To Make Books 'Squeaky Clean' Draws Ire From Edited Writers

Clean Reader — an app designed to find, block and replace profanity in books — has drawn considerable criticism from authors. This week, makers of the app announced they would no longer sell e-books.

Leave a Comment

Help keep the conversation civil. Please refer to our Terms of Use and Code of Conduct before posting your comments.